229 related articles for article (PubMed ID: 31764120)
1. Phosphatidylinositol 3 Kinase δ Inhibitors: Present and Future.
Brown JR
Cancer J; 2019; 25(6):394-400. PubMed ID: 31764120
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
Compagno M; Wang Q; Pighi C; Cheong TC; Meng FL; Poggio T; Yeap LS; Karaca E; Blasco RB; Langellotto F; Ambrogio C; Voena C; Wiestner A; Kasar SN; Brown JR; Sun J; Wu CJ; Gostissa M; Alt FW; Chiarle R
Nature; 2017 Feb; 542(7642):489-493. PubMed ID: 28199309
[TBL] [Abstract][Full Text] [Related]
3. Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia.
Witkowska M; Majchrzak A; Robak P; Wolska-Washer A; Robak T
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):617-633. PubMed ID: 37714711
[TBL] [Abstract][Full Text] [Related]
4. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
Burger JA; Okkenhaug K
Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
[TBL] [Abstract][Full Text] [Related]
5. Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Patel K; Pagel JM
Curr Hematol Malig Rep; 2019 Aug; 14(4):292-301. PubMed ID: 31203516
[TBL] [Abstract][Full Text] [Related]
6. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
7. SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
Fan L; Wang C; Zhao L; Wang Z; Zhang X; Liu X; Cao L; Xu W; Li J
Neoplasia; 2020 Dec; 22(12):714-724. PubMed ID: 33142237
[TBL] [Abstract][Full Text] [Related]
8. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
9. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
11. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Greenwell IB; Flowers CR; Blum KA; Cohen JB
Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
[TBL] [Abstract][Full Text] [Related]
12. Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow.
Ali AY; Guan Q; Wu X; Hou S; Banerji V; Johnston JB; Wall D; Szwajcer D; Gibson SB; Marshall AJ
Br J Haematol; 2019 Jun; 185(5):883-887. PubMed ID: 30873593
[TBL] [Abstract][Full Text] [Related]
13. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Lampson BL; Brown JR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):807-826. PubMed ID: 34174987
[TBL] [Abstract][Full Text] [Related]
15. Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.
Arnason JE; Brown JR
Curr Oncol Rep; 2017 Sep; 19(9):61. PubMed ID: 28755313
[TBL] [Abstract][Full Text] [Related]
16. Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
Future Oncol; 2019 Jul; 15(19):2227-2239. PubMed ID: 31137964
[TBL] [Abstract][Full Text] [Related]
17. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
18. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
Dong S; Guinn D; Dubovsky JA; Zhong Y; Lehman A; Kutok J; Woyach JA; Byrd JC; Johnson AJ
Blood; 2014 Dec; 124(24):3583-6. PubMed ID: 25258342
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
Danilov AV
Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
[TBL] [Abstract][Full Text] [Related]
20. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Scheffold A; Jebaraj BMC; Tausch E; Bloehdorn J; Ghia P; Yahiaoui A; Dolnik A; Blätte TJ; Bullinger L; Dheenadayalan RP; Li L; Schneider C; Chen SS; Chiorazzi N; Dietrich S; Seiffert M; Tannheimer S; Döhner H; Mertens D; Stilgenbauer S
Blood; 2019 Aug; 134(6):534-547. PubMed ID: 31010847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
